ArticleCrohn's & colitis 3602022
Bezlotoxumab Therapy for Recurrent
Article in Crohn's & colitis 360, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immunotherapy restores therapeutic efficacy of fecal microbiome transplants to treatbioRxiv : the preprint server for biology · 2026Article
- Risk factors and outcomes of Clostridioides difficile infection in patients with colorectal cancer: critical perspective in management.Gut pathogens · 2025Review
- Therapeutics involved in managing initial and recurrentWorld journal of gastrointestinal pharmacology and therapeutics · 2024Review
- Bezlotoxumab for prevention ofAnnals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: A single infusion of bezlotoxumab @ 10mg/kg was given with fidaxomicin 200mg for 10 days in a patient with rCDI and ulcerative colitis. Results: The patient's symptoms improved, inflammatory markers normalized, and she has remained asymptomatic for twelve months. Conclusions: This case supports the findings in the MODIFY I/II trials that Bezlotoxumab is a viable treatment option of rCDI in IBD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.